Hidden clues in ovarian tissue: a study hunts for early cancer signals in BRCA carriers
NCT ID NCT07736300
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study investigates whether women with BRCA gene mutations have distinct molecular patterns in their ovarian tissue that could signal the very earliest stages of ovarian cancer. Researchers will analyze gene activity and DNA methylation in tissue samples from 30 women, including BRCA carriers with and without precancerous lesions (STIC) and women without BRCA mutations. The goal is to uncover biomarkers that might one day lead to better risk assessment and earlier detection of ovarian cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify early molecular markers for ovarian cancer risk in BRCA carriers, potentially improving early detection and prevention strategies.
- What could go wrong
- This is a small, exploratory study with only 30 participants. The findings may not translate into clinical tools without much larger validation studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Group A.1: * Age ≥ 18 years * Signed informed consent * Documented germline BRCA1/2 pathogenic variant * Ovarian tissue with no histopathological abnormalities * Availability of archived FFPE tissue from both ovaries * Availability of fimbrial tissue, when present in the archived material Group A.2: * Age ≥ 18 years * Signed informed consent * Documented germline BRCA1/2 pathogenic variant * Ovarian tissue with no histopathological abnormalities * Histologically confirmed unilateral STIC lesion * Availability of archived FFPE tissue from both ovaries * Availability of fimbrial tissue (including fimbria with and without STIC), when present in the archived material Group B: * Age ≥ 18 years * Signed informed consent * Documented germline BRCA1/2 wild-type * Ovarian tissue with no histopathological abnormalities * Availability of archived FFPE tissue from at least one ovary * Availability of fimbrial tissue, when present in the archived material Exclusion Criteria: * Age \< 18 years * Previous or concurrent diagnosis of invasive ovarian, tubal, or peritoneal carcinoma * History of neoadjuvant chemotherapy or pelvic radiotherapy prior to tissue collection * Presence of bilateral STIC lesions * Ovarian or tubal tissue with histopathological abnormalities other than those specified in the inclusion criteria * Inadequate quantity or poor quality of archived FFPE tissue for molecular analyses * Lack of documented germline BRCA1/2 status
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA mutations are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.